Osteopontin biomarker in inflammatory bowel disease, animal models and target for drug discovery

Digestive Diseases and Sciences

Volumn 57, Issue 6, 2012, Pages 1430-1431

  Neuman, Manuela G ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; BIOLOGICAL MARKER; FIBRONECTIN; OSTEOPONTIN; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR RECEPTOR;

CELLULAR IMMUNITY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFECT; DRUG TARGETING; EDITORIAL; ENTERITIS; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS;

ANIMALS; COLITIS; MALE; OSTEOPONTIN; TRINITROBENZENESULFONIC ACID;

EID: 84864290682     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2120-9     Document Type: Editorial

References (24)

1. Neuman MG. Immune dysfunction in inflammatory bowel disease. Trans Res. 2007;149:173-186. (Pubitemid 46442010)
2. Ullman TA, Palmon R. The certain uncertainty of measuring disease activity in IBD. J Clin Gastroenterol. 2007;41:123-125. (Pubitemid 46148650)
3. Meuwis MA, Fillet M, Geurts P, et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol. 2007;73:1422-1433. (Pubitemid 46469959)
4. Glas J, Seiderer J, Bayrle C, et al. The role of osteopontin (OPN/SPP1) haplotypes in the susceptibility to Crohn's disease. PLoS ONE. 2011;6:e29309.
5. Mishima R, Takeshima F, Sawai T, et al. High plasma osteo-pontin levels in patients with inflammatory bowel disease. J Clin Gastroenterol. 2007;41:167-172. (Pubitemid 46148658)
6. Masuda H, Takahashi Y, Asai S, Hemmi A, Takayama T. Osteopontin expression in ulcerative colitis is distinctly different from that in Crohn's disease and diverticulitis. J Gastroenterol. 2005;40:409-413. (Pubitemid 40723931)
7. Masuda H, Takahashi Y, Asai S, Takayama T. Distinct gene expression of osteopontin in patients with ulcerative colitis. J Surg Res. 2003;111:85-90. (Pubitemid 36808703)
8. Hong Q, Dvorak AM. Ultrastructural localization of osteopontin immunoreactivity in phagolysosomes and secretory granules of cells in human intestine. Histochem J. 1997;29:801-812. (Pubitemid 28062666)
9. Gassler N, Autschbach F, Gauer S, et al. Expression of osteopontin (Eta-1) in Crohn disease of the terminal ileum. Scand J Gastroenterol. 2002;37:1286-1295. (Pubitemid 35305766)
10. Sato T, Nakai T, Tamura N, et al. Osteopontin/Eta-1 upregulated in Crohn's disease regulates the Th1 immune response. Gut. 2005;54:1254-1262. (Pubitemid 41192483)
11. Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science. 2000;287:860-864. (Pubitemid 30084330)
12. Gordon JN, MacDonald TT. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease. Gut. 2005;54:1213-1215. (Pubitemid 41192476)
13. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathology. 1997;151:97-110. (Pubitemid 27283962)
14. Jones SC, Banks RE, Haidar A, et al. Adhesion molecules in inflammatory bowel disease. Gut. 1995;36:724-730.
15. Podolsky KD, Lobb R, King N, et al. Attention of colitis in the cotton-top tamarin by anti-a4 integrin monoclonal antibody. J Clin Invest. 1993;92:372-380. (Pubitemid 23209018)
16. Hesterberg P, Windsor-Hines D, Briskin M, et al. Rapid resolution of chronic colitisinthe cotton-top tamarin withan antibodytoa Gut-Homing Integrin α4β7. Gastroenterology. 1996;111:1373-1380. (Pubitemid 26362264)
17. Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gas-troenterol. 2008;24:462-468.
18. Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sørensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease. Scand J Immunol. 2007;65:453-460. (Pubitemid 46632541)
19. Wine E, Shen-Tu G, Gareau MG, et al. Osteopontin mediates Citrobacter rodentium-induced colonic epithelial cell hyperplasia and attaching-effacing lesions. Am J Pathol. 2010;177:1320-1332.
20. Oz HS, Chen TS, Nagasawa H. Comparative efficacies of 2 cysteine prodrugs and a glutathione delivery agent in a colitis model. Trans Res. 2007;150:122-129. (Pubitemid 47081449)
21. Zhong J, Eckhardt ER, Oz HS, Bruemmer D, de Villiers WJ. Osteopontin deficiency protects mice from Dextran sodium sulfate-induced colitis. Inflamm Bowel Dis. 2006;12:790-796. (Pubitemid 44253763)
22. Da Silva AP, Pollett A, Rittling SR, Denhardt DT, Sodek J, Zohar R. Exacerbated tissue destruction in DSS-induced acute colitis of OPN-null mice is associated with downregulation of TNF-alpha expression and non-programmed cell death. J Cell Physiol. 2006;208:629-639. (Pubitemid 44141888)
23. Fan K, Zhang B, Yang H, et al. A humanized anti-osteopontin antibody protects from Concanavalin A induced-liver injury in mice. Eur J Pharmacol. 2011;657:144-151.
24. Oz HS, Zhong J, de Villiers WJS. Osteopontin ablation attenuates progression of colitis in TNBS model. Dig Dis Sci. (Epub ahead of print). doi:10.1007/s10620-011-2009-z.